daclatasvir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals, hepatitis C Virus (HCV) NS5A inhibitors 4875 1009119-64-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • daclatasvir
  • daclatasvir dihydrochloride
  • daclatasvir hydrochloride
  • daklinza
  • BMS-790052-05
  • BMS-790052
  • daclatasvir HCl
  • daclatasivr
an HCV NS5A inhibitor
  • Molecular weight: 738.89
  • Formula: C40H50N8O6
  • CLOGP: 4.72
  • LIPINSKI: 2
  • HAC: 14
  • HDO: 4
  • TPSA: 174.64
  • ALOGS: -4.94
  • ROTB: 13

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
60 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 0.67 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 13.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 27, 2014 EMA
July 24, 2015 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatocellular carcinoma 313.90 30.33 61 3285 1938 50599840
Hepatitis C 172.55 30.33 44 3302 4873 50596905
Genotype drug resistance test positive 140.16 30.33 23 3323 267 50601511
Ascites 123.88 30.33 56 3290 35805 50565973
Hepatic encephalopathy 106.03 30.33 35 3311 9601 50592177
Hepatic failure 79.58 30.33 40 3306 32243 50569535
Fatigue 71.98 30.33 149 3197 707452 49894326
Headache 65.19 30.33 118 3228 506417 50095361
Hepatic cirrhosis 62.36 30.33 28 3318 17549 50584229
Oesophageal varices haemorrhage 60.66 30.33 14 3332 1016 50600762
Liver transplant 55.18 30.33 15 3331 2117 50599661
Hepatitis B reactivation 50.84 30.33 14 3332 2073 50599705
Viral mutation identified 44.69 30.33 12 3334 1617 50600161
Renal impairment 42.19 30.33 37 3309 75624 50526154
Liver injury 42.11 30.33 24 3322 24782 50576996
Jaundice 38.09 30.33 23 3323 26406 50575372
Treatment failure 37.84 30.33 46 3300 137591 50464187
Hepatitis B DNA increased 31.66 30.33 6 3340 165 50601613
Virologic failure 31.31 30.33 9 3337 1555 50600223
Drug resistance 31.23 30.33 18 3328 18971 50582807

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatocellular carcinoma 951.41 24.57 231 5728 6807 29561761
Genotype drug resistance test positive 677.47 24.57 125 5834 898 29567670
Hepatitis C 644.63 24.57 178 5781 8732 29559836
Treatment failure 488.84 24.57 206 5753 36733 29531835
Liver transplant 208.04 24.57 55 5904 2261 29566307
Viral mutation identified 149.08 24.57 43 5916 2445 29566123
Hepatic encephalopathy 136.94 24.57 62 5897 12973 29555595
Drug ineffective 121.85 24.57 241 5718 362929 29205639
Ascites 109.02 24.57 76 5883 36543 29532025
Fatigue 104.51 24.57 209 5750 316612 29251956
Headache 98.38 24.57 146 5813 173861 29394707
Hepatic cirrhosis 98.15 24.57 51 5908 14393 29554175
Hepatic failure 76.88 24.57 58 5901 31454 29537114
Hepatic cancer 75.09 24.57 33 5926 6423 29562145
Virologic failure 73.79 24.57 26 5933 2821 29565747
Therapeutic embolisation 73.18 24.57 16 5943 287 29568281
Hyperbilirubinaemia 66.61 24.57 40 5919 14894 29553674
Hepatitis B reactivation 59.70 24.57 23 5936 3206 29565362
Insomnia 56.56 24.57 79 5880 88682 29479886
Genital herpes simplex 49.56 24.57 10 5949 119 29568449
Biliary colic 47.16 24.57 14 5945 879 29567689
Varices oesophageal 46.27 24.57 19 5940 3127 29565441
Oesophageal varices haemorrhage 42.07 24.57 17 5942 2685 29565883
Hepatitis C RNA increased 41.70 24.57 10 5949 274 29568294
Abdominal cavity drainage 39.77 24.57 10 5949 335 29568233
Genital herpes 39.48 24.57 11 5948 550 29568018
Hepatorenal syndrome 37.60 24.57 15 5944 2291 29566277
Hepatitis C RNA positive 35.62 24.57 8 5951 163 29568405
Jaundice 33.27 24.57 35 5924 29261 29539307
Peritonitis bacterial 29.83 24.57 17 5942 5739 29562829
Embolism 29.52 24.57 18 5941 6878 29561690
Hepatic neoplasm 26.70 24.57 11 5948 1825 29566743
Hydrocholecystis 26.40 24.57 7 5952 290 29568278
Transcatheter arterial chemoembolisation 26.38 24.57 4 5955 6 29568562
Liver disorder 26.04 24.57 30 5929 27719 29540849

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatocellular carcinoma 1138.65 24.56 255 8189 8148 64482140
Hepatitis C 687.34 24.56 179 8265 10836 64479452
Genotype drug resistance test positive 573.49 24.56 102 8342 942 64489346
Treatment failure 261.01 24.56 172 8272 116644 64373644
Hepatic encephalopathy 237.43 24.56 93 8351 20973 64469315
Liver transplant 233.34 24.56 62 8382 4030 64486258
Ascites 214.80 24.56 121 8323 61880 64428408
Viral mutation identified 196.98 24.56 52 8392 3294 64486994
Fatigue 151.21 24.56 313 8131 748417 63741871
Hepatic failure 124.47 24.56 82 8362 55312 64434976
Headache 124.12 24.56 236 8208 529231 63961057
Hepatic cirrhosis 123.78 24.56 63 8381 26235 64464053
Hyperbilirubinaemia 94.57 24.56 49 8395 21156 64469132
Hepatic cancer 91.36 24.56 35 8409 7413 64482875
Hepatitis B reactivation 89.98 24.56 31 8413 4858 64485430
Therapeutic embolisation 89.96 24.56 19 8425 452 64489836
Oesophageal varices haemorrhage 74.59 24.56 25 8419 3604 64486684
Virologic failure 71.72 24.56 24 8420 3442 64486846
Hepatitis C RNA increased 69.93 24.56 15 8429 385 64489903
Insomnia 68.24 24.56 105 8339 197731 64292557
Renal impairment 58.69 24.56 80 8364 134937 64355351
Varices oesophageal 55.46 24.56 22 8422 5108 64485180
Jaundice 53.52 24.56 47 8397 48465 64441823
Drug ineffective 51.27 24.56 231 8213 840016 63650272
Abdominal cavity drainage 50.96 24.56 13 8431 718 64489570
Hepatitis B DNA increased 47.85 24.56 12 8432 618 64489670
Hepatorenal syndrome 47.36 24.56 18 8426 3728 64486560
Genital herpes simplex 45.08 24.56 10 8434 301 64489987
Liver disorder 42.21 24.56 43 8401 53308 64436980
Hepatectomy 38.39 24.56 8 8436 178 64490110
Peritonitis bacterial 34.94 24.56 19 8425 9024 64481264
Biliary colic 34.56 24.56 14 8430 3430 64486858
Hydrocholecystis 33.30 24.56 8 8436 344 64489944
Genital herpes 30.97 24.56 11 8433 1884 64488404
Mesenteric vein thrombosis 30.90 24.56 10 8434 1292 64488996
Hepatitis C RNA positive 30.76 24.56 7 8437 237 64490051
Liver transplant rejection 29.44 24.56 12 8432 2987 64487301
Toxicity to various agents 29.27 24.56 6 8438 363507 64126781
Hepatic neoplasm 29.14 24.56 12 8432 3065 64487223
Acute leukaemia 28.89 24.56 10 8434 1588 64488700
Incorrect product administration duration 28.29 24.56 17 8427 9741 64480547
Portal hypertensive gastropathy 27.80 24.56 9 8435 1163 64489125
Embolism 27.16 24.56 18 8426 12217 64478071
Renal disorder 27.05 24.56 28 8416 35337 64454951
Anaemia 26.66 24.56 109 8335 378571 64111717
Transcatheter arterial chemoembolisation 25.33 24.56 4 8440 16 64490272

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AP07 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HCV infections
ATC J05AP58 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HCV infections
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000190107 Organic Anion Transporting Polypeptide 1B1 Inhibitors
FDA MoA N0000190108 Organic Anion Transporting Polypeptide 1B3 Inhibitors
FDA MoA N0000190113 Breast Cancer Resistance Protein Inhibitors
FDA EPC N0000191256 Hepatitis C Virus NS5A Inhibitor
CHEBI has role CHEBI:36044 antiviral drugs
CHEBI has role CHEBI:83799 nonstructural protein 5A inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chronic hepatitis C indication 128302006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.05 acidic
pKa2 12.44 acidic
pKa3 12.88 acidic
pKa4 13.27 acidic
pKa5 6.51 Basic
pKa6 5.91 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 30MG BASE DAKLINZA BRISTOL-MYERS SQUIBB N206843 July 24, 2015 DISCN TABLET ORAL 8900566 Aug. 8, 2027 METHOD OF INHIBITING HEPATITIS C VIRUS
EQ 30MG BASE DAKLINZA BRISTOL-MYERS SQUIBB N206843 July 24, 2015 DISCN TABLET ORAL 8900566 Aug. 8, 2027 METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
EQ 30MG BASE DAKLINZA BRISTOL-MYERS SQUIBB N206843 July 24, 2015 DISCN TABLET ORAL 9421192 Aug. 8, 2027 METHOD OF INHIBITING HEPATITIS C VIRUS
EQ 30MG BASE DAKLINZA BRISTOL-MYERS SQUIBB N206843 July 24, 2015 DISCN TABLET ORAL 9421192 Aug. 8, 2027 METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
EQ 60MG BASE DAKLINZA BRISTOL-MYERS SQUIBB N206843 July 24, 2015 DISCN TABLET ORAL 8900566 Aug. 8, 2027 METHOD OF INHIBITING HEPATITIS C VIRUS
EQ 60MG BASE DAKLINZA BRISTOL-MYERS SQUIBB N206843 July 24, 2015 DISCN TABLET ORAL 8900566 Aug. 8, 2027 METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
EQ 60MG BASE DAKLINZA BRISTOL-MYERS SQUIBB N206843 July 24, 2015 DISCN TABLET ORAL 9421192 Aug. 8, 2027 METHOD OF INHIBITING HEPATITIS C VIRUS
EQ 60MG BASE DAKLINZA BRISTOL-MYERS SQUIBB N206843 July 24, 2015 DISCN TABLET ORAL 9421192 Aug. 8, 2027 METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
EQ 90MG BASE DAKLINZA BRISTOL-MYERS SQUIBB N206843 April 13, 2016 DISCN TABLET ORAL 9421192 Aug. 8, 2027 METHOD OF INHIBITING HEPATITIS C VIRUS
EQ 90MG BASE DAKLINZA BRISTOL-MYERS SQUIBB N206843 April 13, 2016 DISCN TABLET ORAL 9421192 Aug. 8, 2027 METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
EQ 30MG BASE DAKLINZA BRISTOL-MYERS SQUIBB N206843 July 24, 2015 DISCN TABLET ORAL 8642025 Aug. 11, 2027 METHOD OF INHIBITING HEPATITIS C VIRUS
EQ 30MG BASE DAKLINZA BRISTOL-MYERS SQUIBB N206843 July 24, 2015 DISCN TABLET ORAL 8642025 Aug. 11, 2027 METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
EQ 60MG BASE DAKLINZA BRISTOL-MYERS SQUIBB N206843 July 24, 2015 DISCN TABLET ORAL 8642025 Aug. 11, 2027 METHOD OF INHIBITING HEPATITIS C VIRUS
EQ 60MG BASE DAKLINZA BRISTOL-MYERS SQUIBB N206843 July 24, 2015 DISCN TABLET ORAL 8642025 Aug. 11, 2027 METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
EQ 30MG BASE DAKLINZA BRISTOL-MYERS SQUIBB N206843 July 24, 2015 DISCN TABLET ORAL 8629171 June 13, 2031 METHOD OF INHIBITING HEPATITIS C VIRUS
EQ 60MG BASE DAKLINZA BRISTOL-MYERS SQUIBB N206843 July 24, 2015 DISCN TABLET ORAL 8629171 June 13, 2031 METHOD OF INHIBITING HEPATITIS C VIRUS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 4.53 CHEMBL
Genome polyprotein Polyprotein INHIBITOR EC50 11.05 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Genome polyprotein Polyprotein INHIBITOR EC50 10.30 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Nonstructural protein 5A Unclassified IC50 10.64 CHEMBL

External reference:

IDSource
D10065 KEGG_DRUG
4034682 VUID
N0000191739 NUI
1009119-65-6 SECONDARY_CAS_RN
4034682 VANDF
CHEBI:83800 CHEBI
CHEMBL2023898 ChEMBL_ID
C549273 MESH_SUPPLEMENTAL_RECORD_UI
11266 IUPHAR_LIGAND_ID
9483 INN_ID
DB09102 DRUGBANK_ID
LI2427F9CI UNII
25154714 PUBCHEM_CID
1606217 RXNORM
229788 MMSL
30519 MMSL
d08285 MMSL
015679 NDDF
1172356004 SNOMEDCT_US
712519008 SNOMEDCT_US
714014007 SNOMEDCT_US
C3252090 UMLSCUI
CHEMBL2303621 ChEMBL_ID

Pharmaceutical products:

None